<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158157</url>
  </required_header>
  <id_info>
    <org_study_id>VA-006</org_study_id>
    <nct_id>NCT01158157</nct_id>
  </id_info>
  <brief_title>VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV</brief_title>
  <official_title>Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for
      collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous
      (VIGIV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2010</start_date>
  <completion_date type="Actual">February 14, 2012</completion_date>
  <primary_completion_date type="Actual">February 14, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration</measure>
    <time_frame>Days 0 to 90 post-vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Smallpox Vaccine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Vaccination</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This study was a single arm study. All eligible subjects received ACAM2000.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACAM2000</intervention_name>
    <description>Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.</description>
    <arm_group_label>Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent.

          -  Age 18 - 65 years.

          -  Normal and healthy as determined by medical history, physical exam, vital signs and
             clinical laboratory tests at screening visit.

          -  Subject must meet all required subject suitability criteria that pertain to normal
             Source Plasma donors.

          -  Subject must have been previously immunized for smallpox, at ≥1 year prior to
             commencement of screening assessments for the VA-006 trial, and vaccination history
             must be confirmed by oral or written history AND the presence of a visible
             pathognomonic smallpox vaccination scar.

          -  Female subjects of childbearing potential must use at least one of the following means
             of birth control documented by a physician's letter:

               -  Surgical sterilization

               -  Hormonal (oral/injectable/implant) for at least 30 days prior to vaccination

               -  Intrauterine device (IUD) inserted at least 7 days prior to vaccination.

          -  Female subjects who are not using one of the methods of birth control listed above
             must be documented as postmenopausal, which is defined as not having a menstrual
             period for longer than 12 months and having a serum follicle-stimulating hormone (FSH)
             level ≥ 40 mIU/mL.

        Exclusion Criteria:

          -  History of severe adverse event(s) from previous participation in the VA-001 or VA-005
             trials or any other smallpox vaccination program/study.

          -  Subject, household contact, or other close/intimate contact:

               -  with eczema, history of eczema, exfoliative skin conditions, wounds, burns, or
                  other skin conditions at the Investigator's discretion.

               -  with a history of immunodeficiencies (see section 7.1.2 of the protocol).

               -  who received radiotherapy or chemotherapy, adrenocorticotropic hormone (ACTH),
                  corticosteroids, or immunosuppressive drugs.

               -  with eye disease treated with topical steroids.

               -  with known or suspected disorders of immunoglobulin synthesis.

               -  with leukemia, lymphomas of any type, melanoma, or other malignant neoplasms
                  affecting the bone marrow or lymphatic systems.

               -  with a history of adverse reactions to smallpox (vaccinia) vaccine.

               -  has recently been diagnosed with cancer and who will be undergoing chemotherapy
                  or radiation therapy during the vaccination healing time.

               -  is a transplant recipient (except for corneal transplant).

               -  is pregnant, planning pregnancy or breast feeding (female subjects must have
                  negative serum pregnancy test at screening and negative urine pregnancy test
                  prior to vaccination).

          -  Household or other close/intimate contact(s) under the age of 12 months.

          -  History of allergies to latex, phenol, any of the antibiotics listed in the vaccine
             content, or any other component of ACAM2000 or its diluent

          -  Severely or morbidly obese or higher obesity classification (BMI ≥ 35).

          -  Subjects with abnormal EKG and/or cardiac Troponin levels at screening.

          -  Subjects with cancer or kidney disease (except kidney stones).

          -  Subject has 3 or more of the following risk factors:

               -  High blood pressure diagnosed by a doctor

               -  High blood cholesterol diagnosed by a doctor

               -  Diabetes or high blood sugar diagnosed by a doctor

               -  A first degree relative (for example, mother, father, brother, sister) who had a
                  heart condition before the age of 50

               -  Currently smokes cigarettes

          -  Cardiovascular disease or heart condition diagnosed by a doctor at any time in the
             past, with or without symptoms, including:

               -  Arrhythmia

               -  Syncope

               -  Previous myocardial infarction

               -  Angina

               -  Coronary artery disease

               -  Congestive heart failure

               -  Cardiomyopathy

               -  Stroke or transient ischemic attack

               -  Chest pain or shortness of breath with activity (such as walking up stairs)

               -  Other heart conditions being treated by a physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cangene Plasma Resources, Mid-Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cangene Plasma Resources, Mid-Florida</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://whqlibdoc.who.int/wer/WHO_WER_1980/WER1980_55_145-152%20(N%C2%B020).pdf</url>
    <description>World Health Organization. Declaration of global eradication of smallpox. Wkly. Epidemiol. Rec., 55:145-152, 1980.</description>
  </link>
  <link>
    <url>http://www.cdc.gov/mmwr/</url>
    <description>Centers for Disease Control and Prevention (CDC). Public Health Service recommendations on smallpox vaccination. MMWR, 20:339, 1971.</description>
  </link>
  <link>
    <url>http://www.cdc.gov/mmwr/</url>
    <description>CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP). Smallpox vaccination of hospital and health personnel. MMWR, 25:9, 1976.</description>
  </link>
  <link>
    <url>http://www.cdc.gov/mmwr/</url>
    <description>CDC. Smallpox vaccine no longer available for civilians—United States. MMWR, 32:387, 1983.</description>
  </link>
  <link>
    <url>http://www.cdc.gov/mmwr/</url>
    <description>CDC. Vaccinia (smallpox) vaccine recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR, 40:1-10, 1991.</description>
  </link>
  <reference>
    <citation>Russell PK. Vaccines in civilian defense against bioterrorism. Emerg Infect Dis. 1999 Jul-Aug;5(4):531-3.</citation>
    <PMID>10458959</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 5, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <results_first_submitted>June 7, 2017</results_first_submitted>
  <results_first_submitted_qc>March 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vaccination</title>
          <description>This study was a single arm study. All eligible subjects received ACAM2000.
ACAM2000: Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">61 subjects screened; 25 subjects were vaccinated; 36 subjects were not eligible.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 61 subjects were screened for VA-006 study; 25 subjects satisfied the eligibility criteria and were percutaneously administered ACAM2000 vaccine, while 36 subjects were not eligible for the study and were not administered ACAM2000.</population>
      <group_list>
        <group group_id="B1">
          <title>Vaccination</title>
          <description>This study was a single arm study. All eligible subjects received ACAM2000.
ACAM2000: Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration</title>
        <time_frame>Days 0 to 90 post-vaccination</time_frame>
        <population>Post-vaccination adverse events were assessed in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM200 Vaccination Dose</title>
            <description>Participants received a single percutaneous administration of a droplet (2.5 μL) of the ACAM2000 smallpox vaccine using a bifurcated needle on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration</title>
          <population>Post-vaccination adverse events were assessed in the safety population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>injection site scab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 6 months</time_frame>
      <desc>AE: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</desc>
      <group_list>
        <group group_id="E1">
          <title>ACAM200 Vaccination Dose</title>
          <description>Participants received a single percutaneous administration of a droplet (2.5 μL) of the ACAM2000 smallpox vaccine using a bifurcated needle on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site scab</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine Hall, Ph.D. Director Clinical</name_or_title>
      <organization>Cangene Corporation</organization>
      <phone>204-275-4248</phone>
      <email>chall@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

